Overview

Protreat-Trial: Prophylactic Antiemetic Treatment of Opioid-induced Nausea and Vomiting (OINV) in Palliative Care

Status:
Not yet recruiting

Trial end date:
2023-05-01

Target enrollment:

Participant gender:

Summary

Palliative cancer patients with tumor pain often suffer from nausea and vomiting when starting pain therapy with opioids. The objective of the clinical pilot trial is to evaluate the efficacy and tolerability of palonosetron in the prophylactic treatment of opioid-induced nausea and vomiting.

Phase:

Phase 2

Details

Lead Sponsor:

Gerhild Becker

Treatments:

Palonosetron